Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista Colombiana de Cardiología
Print version ISSN 0120-5633
Abstract
MANZUR, Fernando; VILLARREAL, Tatiana and MONERIZ, Carlos. Dual inhibition of neprilysin and angiotensin II receptor: promising new strategy in the treatment of cardiovascular disease. Rev. Colomb. Cardiol. [online]. 2013, vol.20, n.6, pp.386-393. ISSN 0120-5633.
Neprilysin inhibition and angiotensin II receptor blockade offer potential benefits for the treatment of cardiovascular diseases. The compound LCZ696 is the first drug under study phase as an inhibitor of neprilysin and angiotensin receptors . The increase of the concentration of the natriuretic peptides through the inhibition of neprilysin represents a therapeutic approach which has the potential of conferring cardiac, renal and vascular protection. However, several studies show that the clinical benefits of neprilysin inhibition can be better utilized if the renin-angiotensin system is simultaneously inhibited. This review realized in PubMed aims to present the promising advances in the dual mechanism of inhibition of neprilysin and angiotensin II receptor for the treatment of hypertension and heart failure.
Keywords : angiotensin; hypertension; heart failure; natriuretic peptides.